

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Bausch Health
Deal Size : $413.0 million
Deal Type : Acquisition
Bausch Health Completes Acquisition of DURECT Corporation
Details : Through the acquisition, Basuch will leverage DURECT's lead asset, DUR-928 (Larsucosterol), is an epigenetic modulator. It is being evaluated for alcoholic hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $63.0 million
September 11, 2025
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Bausch Health
Deal Size : $413.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DURECT Announces Phase 3 Trial Design for Larsucosterol in Alcohol-Associated Hepatitis
Details : DUR-928 (larsucosterol) is an endogenous sulfated oxysterol and an epigenetic modulator, that inhibits DNA methylation. It is being evaluated for the treatment of alcohol-associated hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Breakthrough Therapy Status To DURECT's Larsucosterol For Hepatitis
Details : DUR-928 (larsucosterol) is an endogenous sulfated oxysterol and an epigenetic modulator, that inhibits DNA methylation. It is being evaluated for the treatment of alcohol-associated hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2023
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2023
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $10.0 million
Deal Type : Public Offering
DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants
Details : DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $10.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
Details : Larsucosterol (DUR-928) is an endogenous sulfated oxysterol and an epigenetic regulator. Epigenetic regulators are compounds that regulate patterns of gene expression without modifying the DNA sequence.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study comprised enrollment of 300 patients, with 100 patients in each arm for DUR-928 (larsucosterol), inhibits activity of DNMTs, epigenetic enzymes in AH Patients. Primary outcome measure is 90-day survival rate for patients treated with DUR-928 compar...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2022
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The potential of epigenetic regulator candidate, larsucosterol (also known as DUR-928) is to improve inflammation, cell death, and tissue regeneration in severe Alcohol-Associated Hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2021
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Larsucosterol (also known as DUR-928), the Company's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in AH patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Inapplicable
Deal Type : Inapplicable
